Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 17/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.77 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.77 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.77 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.77 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | LTA4H | P09960 | 1/20 | 0.77 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064861 | 1.00 | HDAC4 (0.77) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1060805 | 0.98 | HDAC4 (0.73) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL3806017 | 0.94 | MEN1 (0.73) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6669511 | 0.94 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6665592 | 0.94 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL137348 | 0.94 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1065393 | 0.94 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL517309 | 0.92 | HDAC4 (0.81) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| Hydroxyamine SCHEMBL1268824 | 0.90 | HDAC6 (0.79) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6296181 | 0.88 | HDAC4 (0.75) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011061545-A1 | HPLC METHOD FOR ANALYZING VORINOSTAT | GENERICS [UK] LIMITED (GB) | 2011-05-26 | — | — | WO | claimed |
| WO-2026102197-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260125343-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | UNRAVEL BIOSCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| CN-121926915-A | Application of 7-phenylcarbamoyl heptanoic acid in preparation of antitumor drugs | 山东大学 | 2026-04-28 | — | — | CN | disclosed |
| CN-121926915-A | Application of 7-phenylcarbamoyl heptanoic acid in preparation of antitumor drugs | 山东大学 | 2026-04-28 | — | — | CN | disclosed |
| WO-2024218227-A1 | INDOLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSIDAD DE ALCALÁ (ES) | 2024-10-24 | — | — | WO | disclosed |
| EP-4450494-A1 | INDOLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | Consejo Superior De Investigaciones Científicas (ES) | 2024-10-23 | — | — | EP | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | XAVIER UNIVERSITY OF LOUISIANA (US) | 2021-06-29 | — | — | US | disclosed |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | MERCK & CO., INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-15 | — | — | US | disclosed |
| WO-2006127321-A2 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127319-A2 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1692097-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | Exonhit Therapeutics SA (FR) | 2006-08-23 | — | — | EP | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541549-A1 | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods | Exonhit Therapeutics S.A. (FR) | 2005-06-15 | — | — | EP | disclosed |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC7 5/4885 |
| US-20040127523-A1 | safe, daily dosing regimen of histone deacetylase (HDAC) inhibitors having favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time | HDAC1, HDAC5, HDAC9 | HDAC4 5/4885HDAC1 1/4885HDAC7 10/4885 |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC7 7/4885 |
| US-20040132825-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC4 4/4885HDAC1 3/4885HDAC7 7/4885 |
| US-20070060614-A1 | Methods of treating cancer with hdac inhibitors | HDAC5, BCL6, HDAC9 | HDAC4 4/4885HDAC1 5/4885HDAC7 9/4885 |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | HDAC4 1236/4885HDAC1 602/4885HDAC7 1863/4885 |
| US-20260125343-A1 | METHODS FOR PREPARING HIGH-PURITY VORINOSTAT AND PRECURSORS THEREOF | HDAC8, HDAC7, SUB1 | HDAC4 7/4885HDAC1 4/4885HDAC7 2/4885 |
| US-11046715-B2 | Boronic derivatives of hydroxamates as anticancer agents | BCOR, BRDT, HDAC1 | HDAC4 15/4885HDAC1 3/4885HDAC7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.